+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language

Nitrosamine in-depth examination: updates and news – October 2024

Nitrosamine

This article intends to provide an in-depth picture of the regulation updates as well as the main critical issues related to the presence of nitrosamine impurities in medicinal products, through a review of the reference regulations and an examination of the issues arising during the monitoring and management of such impurities, with special attention on the aspects related to safety, and quality of pharmaceutical products.

These impurities, first identified in 2018 in the category of medicinal products known as “sartans”, are substances classified as potential carcinogens and mutagens in humans and can be present in various types of food and water, so that most people is daily exposed to small amounts.

Assessment on potential damage

Actually, the European Food Safety Authority (EFSA) has also carried out an in-depth assessment to estimate the potential damages from nitrosamines on human and animal health, also examining the level of exposure of consumers to these substances concluding that for all age groups of the European population the level of exposure to nitrosamines arouses health concerns.

In the pharmaceutical sector, their presence does not depend only from the synthesis conditions of the active substance (API), but can also derive from the manufacturing process of finished pharmaceutical forms, in particular from starting materials used, reagents, solvents, packaging materials and from some processing steps.

In medicines, the presence of nitrosamines is not considered as acceptable, therefore Regulatory Authorities maintain a constant focus on the topic, and have adopted preventive measures such as withdrawal of batches from the market and mandatory nitrosamine contamination risk analysis.

AIFA has set up a Working Group (GDL) to share a common approach with other European and extra-European authorities on how to ensure the quality and safety of the manufactured products.

Nitrosamine Working Day

During a recent working day organised by AFI, some of the EMA updates in the regulations were illustrated along with more and more aimed actions to control these substances by the individual Regulatory Authorities.

These include the revision of the draft “Guideline on the chemistry of active substance” that has introduced new custom-made strategies for control to reduce the risk of nitosamine contamination, available for consultation until 31 January 2025.

In July 2024 a new update of the Q&As was released for marketing authorization holders, on the CHMP opinion on the reference to article 5 of Regulation (EC) no. 726/2004.

During the meeting, Ms Galatti and Ms  Vitocolonna  of the AIFA made speeches where they presented the European and Italian regulatory picture, stressing the importance to continuously update risk assessments, in compliance with the deadlines established by the Authority and with the following updates; one of these, the communication of July 2023 introducing the new approach to classify the new nitrosamine impurities, the so called CPCA (Carcinogenic Potency Categorization Approach).

What should marketing authorisation holder do?

The task of the MA holders/Applicants is to regularly monitor any update in the Q&A document and in Appendix 1, already separated by revision 10, that are constantly updated in the light of new evidence.

Products showing levels of nitrosamines above the Acceptable Intake (AI) should be evaluated by the competent Authorities and by the European networks created to this purpose. In this cases, MA holder shall take corrective actions (CAPA) to reduce the risk of contamination.

Temporary limits (ad interim or LTL) can be proposed to prevent discontinuations in the market supplies for products that have CAPA implementing times up to 3 years.

On this regard, the generic temporary safety limit of 178 ng/day, introduced in December 2022 and only applicable for 12 months waiting for the CAPA implementation, is now obsolete and not applicable anymore.

The risk assessment on the presence of nitrosamines is also essential for investigational drugs, since it is important  to ensure the product quality as early as the initial steps of development, to prevent any future problems.

A Quality by design  approach is particularly effective in preventing any nitrosamine contamination risk, since it allows to obtain a more sound and systematic control of the product quality, avoiding expensive changes in advanced developmental stages or, even worse, in the final product.

Conclusions

Maintaining a continuous cooperation between marketing authorisation holders and manufacturers, of APIs as well as of finished products, is essential to ensure the safety of medicinal products along the whole product lifecycle.

Paying attention to nitrosamines requires constant updating on the best practice  to follow to mitigate the risks associated with these impurities.

Moreover, the debate among professionals in the field is crucial to face the challenges related to drug safety. Finally, it is essential that operators in the field maintain a high level of vigilance and proactivity in the management of nitrosamine impurities, as the assessment of the risk of formation of these substances should be seen as continuous and dynamic process.

Written on 18/10/2024 by Anna Pia Dima and Juliana Bundo